Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The focus is on wellness and personal care products
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
It strengthens its presence to over 250 stores
Subscribe To Our Newsletter & Stay Updated
